Lytgobi (futibatinib) / Otsuka  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lytgobi (futibatinib) / Otsuka
jRCT2080224975: A Phase 1b Study of TAS-120 and Pembrolizumab

Completed
1b
223
Japan
Lytgobi (futibatinib) - Otsuka
Taiho Pharmaceutical Co., Ltd.
Patients with advanced or metastatic esophageal carcinoma or non-small-cell lung cancer
 
 
NCT04965818: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Terminated
1
38
US
Futibatinib and Binimetinib
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
06/23
09/23
NCT04999761: AB122 Platform Study

Recruiting
1
715
Japan
AB122, TAS-116, TAS-120, TAS-115, TAS-102, Ramucirumab, Bevacizumab
Taiho Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma
05/26
05/26
POTENTIATE, NCT05827614: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications

Recruiting
1
150
US
BBI-355, Erlotinib, Futibatinib
Boundless Bio
Non-small Cell Lung Cancer, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Liposarcoma
09/26
09/27

Download Options